It is now looking like treating your potential PTSD disorder could eventually become a more fun and positive experience. The American Food and Drug Administration (FDA) has just approved the use of Methylenedioxymethamphetamine for clinical trials. If you haven’t been able to pronounce that, then you’re a normal person, as the drug is commonly called MDMA or Ecstasy.
The surprising fact about this last approval is that MDMA has long been vilified. It is very widely sold underground illegally as a party drug and more specifically a psychedelic. It reportedly heightens your senses and gives you a very sociable and outgoing attitude that partygoers actively look for. Regardless, this Schedule 1 substance, as classified by the American government, has just gotten its biggest advancement yet by being allowed to move to the next step of an ongoing research into its use the treatment of Post-traumatic Stress Disorder.
In order to get this approval, the researchers have proved that if the substance is used under controlled parameters, it could eventually have very beneficial effects on treating many psychological disorders such as social anxiety and depression all the while posing zero safety risks.
In the previous stages of the research, multiple clinical trials were conducted on a very limited scale. But now with this approval, the Multidisciplinary Association for Psychedelic Studies (MAPS) is allowed to conduct the trials on a much larger cohort of subjects, which is usually the last step that a substance goes through before becoming a commercialized medicine.
This last stage will see PTSD patients being given MDMA once a month for three months during controlled psychotherapy sessions. Once this is done, the MAPS organization hopes to have the drug become a viable option for treatment of the disorder by 2021.